We used immunohistochemistry to detect the expression frequency of glypican-3 (GPC3) in OCCC, which is a well-recognized diagnostic marker of the hepatocellular carcinoma and highly heterogeneous in other cancers such as OCCC [19, 20], so as to provide a clear clinical basis for future drug development. This evidence concerns the gene GPC3 and cancer.